Treace Medical Concepts, Inc. TMCI
We take great care to ensure that the data presented and summarized in this overview for TREACE MEDICAL CONCEPTS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TMCI
View all-
Armistice Capital, LLC New York, NY6.21MShares$34.7 Million0.79% of portfolio
-
Black Rock Inc. New York, NY4.07MShares$22.7 Million0.0% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.1MShares$17.3 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.71MShares$15.1 Million0.0% of portfolio
-
Cibc Private Wealth Group, LLC2.29MShares$12.8 Million0.04% of portfolio
-
Gagnon Securities LLC2.25MShares$12.6 Million2.84% of portfolio
-
Jpmorgan Chase & CO New York, NY1.85MShares$10.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.53MShares$8.56 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.28MShares$7.18 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.09MShares$6.08 Million0.0% of portfolio
Latest Institutional Activity in TMCI
Top Purchases
Top Sells
About TMCI
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Insider Transactions at TMCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 18
2025
|
Sean F. Scanlan Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,437
+8.02%
|
$0
$0.72 P/Share
|
|
May 20
2025
|
John K Bakewell |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+12.08%
|
-
|
|
May 20
2025
|
Richard W Mott |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+2.13%
|
-
|
|
May 20
2025
|
Betsy Hanna |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+34.58%
|
-
|
|
May 20
2025
|
Jane E Kiernan |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+27.22%
|
-
|
|
May 20
2025
|
Lawrence W Hamilton |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+35.19%
|
-
|
|
May 20
2025
|
Lance A Berry |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+34.91%
|
-
|
|
May 20
2025
|
Deepti Jain |
BUY
Grant, award, or other acquisition
|
Direct |
23,917
+25.4%
|
-
|
|
May 08
2025
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
SELL
Payment of exercise price or tax liability
|
Direct |
1,894
-0.33%
|
$13,258
$7.54 P/Share
|
|
May 08
2025
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
BUY
Grant, award, or other acquisition
|
Direct |
7,775
+1.33%
|
-
|
|
Mar 17
2025
|
Sean F. Scanlan Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
50,000
-12.07%
|
$350,000
$7.97 P/Share
|
|
Mar 17
2025
|
Sean F. Scanlan Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+10.77%
|
$50,000
$1.05 P/Share
|
|
Mar 10
2025
|
Mark Hair Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,684
-0.68%
|
-
|
|
Mar 10
2025
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
SELL
Payment of exercise price or tax liability
|
Direct |
1,675
-0.29%
|
-
|
|
Mar 10
2025
|
Sean F. Scanlan Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,396
-0.38%
|
-
|
|
Mar 10
2025
|
John T. Treace Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,021
-0.07%
|
-
|
|
Mar 10
2025
|
Aaron Berutti SVP, Sales |
SELL
Payment of exercise price or tax liability
|
Direct |
1,815
-0.86%
|
-
|
|
Mar 08
2025
|
Mark Hair Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
961
-0.18%
|
-
|
|
Mar 08
2025
|
Scot Michael Elder Chief Legl & Comp Off, CorpSec |
SELL
Payment of exercise price or tax liability
|
Direct |
176
-0.03%
|
-
|
|
Mar 08
2025
|
Sean F. Scanlan Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
401
-0.11%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.03M shares |
|---|---|
| Open market or private purchase | 279K shares |
| Exercise of conversion of derivative security | 117K shares |
| Payment of exercise price or tax liability | 58.3K shares |
|---|---|
| Open market or private sale | 50K shares |